238 related articles for article (PubMed ID: 12594668)
1. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma.
O'Suilleabhain CB; Poon RT; Yong JL; Ooi GC; Tso WK; Fan ST
Br J Surg; 2003 Mar; 90(3):325-31. PubMed ID: 12594668
[TBL] [Abstract][Full Text] [Related]
2. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients.
Takayasu K; Arii S; Ikai I; Omata M; Okita K; Ichida T; Matsuyama Y; Nakanuma Y; Kojiro M; Makuuchi M; Yamaoka Y;
Gastroenterology; 2006 Aug; 131(2):461-9. PubMed ID: 16890600
[TBL] [Abstract][Full Text] [Related]
3. Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B: results of a comparative study in 96 Chinese patients.
Yuen MF; Chan AO; Wong BC; Hui CK; Ooi GC; Tso WK; Yuan HJ; Wong DK; Lai CL
Am J Gastroenterol; 2003 May; 98(5):1181-5. PubMed ID: 12809846
[TBL] [Abstract][Full Text] [Related]
4. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
[TBL] [Abstract][Full Text] [Related]
5. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors.
Ueno K; Miyazono N; Inoue H; Nishida H; Kanetsuki I; Nakajo M
Cancer; 2000 Apr; 88(7):1574-81. PubMed ID: 10738215
[TBL] [Abstract][Full Text] [Related]
6. Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.
Hsu CY; Huang YH; Su CW; Lin HC; Chiang JH; Lee PC; Lee FY; Huo TI; Lee SD
Liver Int; 2010 Jan; 30(1):77-84. PubMed ID: 19818004
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma.
Mabed M; Esmaeel M; El-Khodary T; Awad M; Amer T
Eur J Cancer Care (Engl); 2009 Sep; 18(5):492-9. PubMed ID: 19453695
[TBL] [Abstract][Full Text] [Related]
8. [A comparison of patients with hepatocellular carcinoma between a short-term (less than 6 months) survival group and a long-term (over 24 months) survival group after treatment with transcatheter arterial chemoembolization].
Kang IK; Kim SW; Hahn SH; Cho SC; Gham CW; Lee DH
Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):189-200. PubMed ID: 12499805
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
[TBL] [Abstract][Full Text] [Related]
10. Liver failure after transarterial chemoembolization for patients with hepatocellular carcinoma and ascites: incidence, risk factors, and prognostic prediction.
Hsin IF; Hsu CY; Huang HC; Huang YH; Lin HC; Lee RC; Chiang JH; Lee FY; Huo TI; Lee SD
J Clin Gastroenterol; 2011 Jul; 45(6):556-62. PubMed ID: 21666547
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
[TBL] [Abstract][Full Text] [Related]
12. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey.
Huo T; Huang YH; Wu JC; Chiang JH; Lee PC; Chang FY; Lee SD
Aliment Pharmacol Ther; 2004 Jun; 19(12):1301-8. PubMed ID: 15191512
[TBL] [Abstract][Full Text] [Related]
13. Chemoembolization for hepatocellular carcinoma: multivariate analysis of predicting factors for tumor response and survival in a 362-patient cohort.
Hu HT; Kim JH; Lee LS; Kim KA; Ko GY; Yoon HK; Sung KB; Gwon DI; Shin JH; Song HY
J Vasc Interv Radiol; 2011 Jul; 22(7):917-23. PubMed ID: 21571545
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes.
Yoon SM; Lim YS; Won HJ; Kim JH; Kim KM; Lee HC; Chung YH; Lee YS; Lee SG; Park JH; Suh DJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2004-11. PubMed ID: 21621346
[TBL] [Abstract][Full Text] [Related]
15. Reappraisal of repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma with portal vein invasion.
Kim KM; Kim JH; Park IS; Ko GY; Yoon HK; Sung KB; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Gastroenterol Hepatol; 2009 May; 24(5):806-14. PubMed ID: 19207681
[TBL] [Abstract][Full Text] [Related]
16. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization.
Hiraoka A; Horiike N; Yamashita Y; Koizumi Y; Doi H; Yamamoto Y; Ichikawa S; Hasebe A; Yano M; Miyamoto Y; Ninomiya T; Ootani H; Takamura K; Kawasaki H; Otomi Y; Kogame M; Sogabe I; Ishimaru Y; Kashihara K; Miyagawa M; Hirooka M; Hiasa Y; Matsuura B; Michitaka K; Onji M
Hepatogastroenterology; 2009; 56(89):213-7. PubMed ID: 19453060
[TBL] [Abstract][Full Text] [Related]
18. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors.
Mondazzi L; Bottelli R; Brambilla G; Rampoldi A; Rezakovic I; Zavaglia C; Alberti A; Idèo G
Hepatology; 1994 May; 19(5):1115-23. PubMed ID: 7513677
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
20. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival.
Grieco A; Marcoccia S; Miele L; Marmiroli L; Caminiti G; Ragazzoni E; Cotroneo AR; Cefaro GA; Rapaccini GL; Gasbarrini G
Hepatogastroenterology; 2003; 50(49):207-12. PubMed ID: 12630024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
